Treatment of advanced or metastatic hepatocellular cancer (HCC): Final clinical results of a single-arm phase II study of bevacizumab and everolimus

被引：0
|
作者：
Treiber, Gerhard
Wex, Thomas
Schneider, Guenther
Roecken, Cristoph
Dufour, Jean-Francois
Geisel, Juergen
Hardikar, S.
机构：
[1] Zollernalb Clin, Dept Internal Med, Balingen, Germany
[2] Otto von Guericke Univ Hosp, Clin Gastroenterol Hepatol & Infect Dis, Magdeburg, Germany
[3] Saarland Univ Hosp, Dept Diagnost & Intervent Radiol, Homburg, Germany
[4] Univ Kiel, Inst Pathol, Kiel, Germany
[5] Univ Bern, Dept Clin Pharmacol, Bern, Switzerland
[6] Saarland Univ Hosp, Dept Clin Chem, Homburg, Germany
[7] Novartis Asia Pacific Pharmaceut, Singapore, Singapore
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2012年 / 30卷 / 15期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
4107
引用
收藏
页数：1
相关论文
共 50 条
  • [1] Treatment of Advanced or Metastatic Hepatocellular Cancer (HCC) - Clinical Results of a Single-ARM Phase II Study of Bevacizumab and Everolimus
    Treiber, Gerhard
    GASTROENTEROLOGY, 2012, 142 (05) : S922 - S922
  • [2] Treatment of advanced or metastatic hepatocellular cancer (HCC): Interim analysis of a single-arm phase II study of bevacizumab and RAD001
    Treiber, G.
    JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (15)
  • [3] Treatment of Advanced or Metastatic Hepatocellular Cancer (HCC) Preliminary Safety Analysis of a Single-ARM Phase II Study of Bevacizumab and Rad001
    Treiber, Gerhard
    GASTROENTEROLOGY, 2010, 138 (05) : S811 - S811
  • [4] Treatment of advanced or metastatic hepatocellular cancer (HCC) - preliminary safety analysis of a single-arm phase II study of bevacizumab and RAD001
    Treiber, G.
    ONKOLOGIE, 2010, 33 : 8 - 9
  • [5] Modified-dose capecitabine plus bevacizumab for the treatment of advanced/metastatic hepatocellular carcinoma (HCC): A phase II, single-arm study
    Hsu, C.
    Yang, T.
    Hsu, C.
    Toh, H.
    Epstein, R. J.
    Hsiao, L.
    Cheng, A.
    JOURNAL OF CLINICAL ONCOLOGY, 2007, 25 (18)
  • [6] Thalidomide plus tegafur/uracil for the treatment of advanced/metastatic hepatocellular carcinoma (HCC): A phase II single-arm study
    Hsu, C.
    Chang, D.
    Lin, Z.
    Lee, K.
    Hsiao, C.
    Shen, Y.
    Cheng, A.
    Hsu, C.
    JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (15)
  • [7] Toripalimab plus bevacizumab as first-line treatment for advanced hepatocellular carcinoma: A single-arm phase II study
    Hao, Chunyi
    Du, Chengyou
    Peng, Baogang
    Zhang, Wu
    Shan, Yunfeng
    Lv, Ang
    Wu, Jianhui
    Shang, Changzhen
    Luo, Xuan
    Wei, Jinxing
    Xiao, Heng
    Qiu, Jianguo
    Hua, Yunpeng
    Shen, Shunli
    Wang, Ting
    Dai, Shengjie
    Chen, Xiang
    Yan, Shican
    Hao, Chunyi
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (04)
  • [8] FOLFOX-HAIC combined with sintilimab and bevacizumab for advanced hepatocellular carcinoma: A single-arm, phase II study
    Wang, Z.
    Zheng, C.
    Liang, B.
    ANNALS OF ONCOLOGY, 2024, 35 : S1483 - S1483
  • [9] Phase II study of bevacizumab (A) plus capecitabine (X) in patients (pts) with advanced/metastatic hepatocellular carcinoma (HCC): Final report
    Hsu, C.
    Yang, T.
    Hsu, C.
    Toh, H.
    Epstein, R.
    Hsiao, L.
    Lin, Z.
    Cheng, A.
    JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (15)
  • [10] Primary results from CECILIA, a global single-arm phase II study evaluating bevacizumab, carboplatin and paclitaxel for advanced cervical cancer
    Redondo, Andres
    Colombo, Nicoletta
    McCormack, Mary
    Dreosti, Lydia
    Nogueira-Rodrigues, Angelica
    Scambia, Giovanni
    Lorusso, Domenica
    Joly, Florence
    Schenker, Michael
    Ruff, Paul
    Estevez-Diz, Maria
    Irahara, Natsumi
    Donica, Margarita
    Gonzalez-Martin, Antonio
    GYNECOLOGIC ONCOLOGY, 2020, 159 (01) : 142 - 149
12345